GOSS
Gossamer Bio Soars Ahead: Q1 2026 Earnings Call Highlights Regulatory Progress, Therapeutic Breakthroughs
Gossamer Bio has made significant strides in its first quarter of 2026, as reported during their recent earnings call. The biotech company's Chief Operating Officer and Chief Financial Officer, Bryan Giraudo, welcomed investors to the conference call, where they discussed three key topics: regulatory updates, clinical trial results,